Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Headlands Technologies LLC

Headlands Technologies LLC reduced its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 2.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,085 shares of the biopharmaceutical company’s stock after selling 493 shares during the period. Headlands Technologies LLC’s holdings in Royalty Pharma were worth $648,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Allworth Financial LP raised its position in shares of Royalty Pharma by 89.8% during the 3rd quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 451 shares in the last quarter. Toroso Investments LLC grew its stake in shares of Royalty Pharma by 0.9% in the third quarter. Toroso Investments LLC now owns 57,102 shares of the biopharmaceutical company’s stock worth $1,550,000 after purchasing an additional 504 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Royalty Pharma by 112.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 531 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Royalty Pharma by 10.8% in the third quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 536 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. boosted its stake in Royalty Pharma by 8.0% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 8,210 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 607 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on RPRX shares. Bank of America decreased their target price on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 11th. JPMorgan Chase & Co. decreased their target price on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research note on Tuesday, February 20th. Finally, The Goldman Sachs Group decreased their target price on Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Royalty Pharma presently has an average rating of “Buy” and an average price target of $46.75.

Royalty Pharma Trading Down 0.4 %

Shares of NASDAQ RPRX traded down $0.11 during mid-day trading on Friday, hitting $28.00. 1,748,254 shares of the company traded hands, compared to its average volume of 2,545,847. Royalty Pharma plc has a 1 year low of $25.92 and a 1 year high of $35.76. The stock has a market capitalization of $16.73 billion, a price-to-earnings ratio of 14.81 and a beta of 0.45. The company has a quick ratio of 7.90, a current ratio of 7.90 and a debt-to-equity ratio of 0.61. The business has a 50 day moving average of $29.61 and a two-hundred day moving average of $28.55.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.12. The firm had revenue of $736.00 million during the quarter, compared to the consensus estimate of $702.90 million. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. On average, sell-side analysts anticipate that Royalty Pharma plc will post 3.95 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 3.00%. The ex-dividend date of this dividend is Thursday, May 16th. Royalty Pharma’s dividend payout ratio is currently 44.44%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.